FATE THERAPEUTICS INC quarterly report, Q3 FY2016

Fate Therapeutics, Inc. — Q3 2016 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2016. The company is a clinical-stage biopharmaceutical developer of programmed cellular immunotherapies and has not generated revenue from product sales; reported revenue comes from collaborations and grants.

Financial results and position

MetricQ3 2016Q3 2015Nine months 2016Nine months 2015
Collaboration revenue$1.0 million$1.0 million$3.4 million$1.4 million
Research and development$6.8 million$5.0 million$20.2 million$14.4 million
General and administrative$2.6 million$2.4 million$7.5 million$7.8 million
Net loss$8.7 million$6.9 million$25.5 million$22.5 million
Basic and diluted loss per share$0.27$0.24$0.85$0.92

For Q3, operating expenses rose 28% year over year, mainly from higher clinical, research-service and personnel costs. Revenue was unchanged, and net loss widened. For the nine-month period, revenue increased by $2.0 million, primarily with increased Juno research activity, while R&D expense rose by $5.8 million. G&A declined modestly. The filing does not present product gross margins; revenue is collaboration-based.

  • Cash and liquidity: Cash and cash equivalents were $37.1 million at September 30, down from $64.8 million at December 31, 2015. Short-term U.S. Treasury investments were $9.5 million, bringing cash and investments to $46.6 million. Current assets were $47.4 million and current liabilities $14.7 million.
  • Cash flow: Nine-month operating cash use was $22.3 million versus $11.4 million in 2015. Investing used $10.1 million, including net Treasury purchases; financing provided $4.7 million, including $10.2 million net proceeds from an August private placement, partly offset by $5.7 million of debt principal payments. Cash declined by $27.7 million.
  • Debt: Debt principal was $12.7 million at quarter-end, with $8.1 million classified as current. The Silicon Valley Bank loans bear fixed interest of 6.94% and 7.07% and mature in 2018. They are secured by substantially all company assets, excluding certain intellectual property.
  • Equity: The August 2016 private placement issued 5.25 million shares at $1.96 per share for $10.2 million net proceeds. Shares outstanding were 34.1 million at September 30, versus 28.7 million at December 31, 2015.

Business developments, outlook and risks

  • The lead clinical program is ProTmune, in Phase 1/2 development for prevention of graft-versus-host disease and cytomegalovirus infection in patients undergoing hematopoietic cell transplantation. Other programs include preclinical NK- and T-cell cancer therapies and immuno-regulatory programs.
  • Under the Juno collaboration, Juno funds research with minimum annual payments of $2.0 million during the initial four-year term, which began in 2015. Fate recognized $3.4 million of related revenue in the first nine months of 2016 and reported $5.5 million of Juno-related deferred revenue at quarter-end. Contingent selection fees, milestones and royalties had not been received.
  • Management said existing cash and short-term investments were expected to fund projected operations for at least the next 12 months. The company expects continuing and increasing operating losses, higher R&D spending, and a need for additional capital; funding may not be available on acceptable terms.
  • Key risks include clinical and regulatory uncertainty, patient enrollment, manufacturing consistency and reliance on transplant-center facilities and third-party suppliers, including mobilized peripheral blood; further financing and dilution; and dependence on Juno for collaboration funding and potential contingent payments. Juno’s milestone and royalty amounts are conditional, not assured revenue.
  • The company extended its facilities lease through June 2023 and added approximately 24,000 square feet; aggregate future minimum lease payments were $14.5 million. Management reported effective disclosure controls and no material legal proceedings.

Important facts for investors to verify

  • Whether the ProTmune Phase 1/2 trial progresses on schedule and produces safety and efficacy results sufficient to support further development.
  • Whether the stated 12-month cash runway remains realistic given operating cash use, planned R&D increases, debt repayments and lease commitments.
  • Current cash, investment balances, debt repayment schedule and compliance with Silicon Valley Bank loan covenants.
  • Juno collaboration research funding, continuation or extension decisions, and whether any target-selection, milestone or royalty payments become achievable.
  • Potential dilution from registered resale shares, future financing and the company’s shelf registration statement.